BlackRock
CBIO

BlackRock’s Crescent Biopharma CBIO Stock Holding History

BlackRock’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9M Buy
1,271,762
+1,156,037
+999% +$22.6M ﹤0.01% 3165
2026
Q1 		$2.13M Buy
115,725
+6,495
+6% +$74.6K ﹤0.01% 4124
2025
Q4 		$1.3M Buy
109,230
+115
+0.1% +$1.47K ﹤0.01% 4231
2025
Q3 		$1.3M Buy
109,115
+103,064
+1,703% +$1.37M ﹤0.01% 4214
2025
Q2 		$97.7K Sell
6,051
-1,212
-17% -$25.6K ﹤0.01% 4848
2025
Q1 		$153K Sell
7,263
-23
-0.3% -$615 ﹤0.01% 4659
2024
Q4 		$181K Buy
7,286
+7
+0.1% +$191 ﹤0.01% 4641
2024
Q3 		$123K Buy
7,279
+47
+0.6% +$986 ﹤0.01% 4632
2024
Q2 		$204K Sell
7,232
-94
-1% -$9.77K ﹤0.01% 4544
2024
Q1 		$2.2M Sell
7,326
-24
-0.3% -$7.17K ﹤0.01% 3972
2023
Q4 		$1.73M Buy
7,350
+3
+0% +$466 ﹤0.01% 4090
2023
Q3 		$1.1M Sell
7,347
-492
-6% -$77.6K ﹤0.01% 4214
2023
Q2 		$1.36M Buy
7,839
+1,350
+21% +$226K ﹤0.01% 4206
2023
Q1 		$818K Sell
6,489
-1,098
-14% -$247K ﹤0.01% 4390
2022
Q4 		$2.3M Sell
7,587
-72
-0.9% -$10.6K ﹤0.01% 4079
2022
Q3 		$423K Sell
7,659
-24
-0.3% -$1.73K ﹤0.01% 4771
2022
Q2 		$459K Sell
7,683
-999
-12% -$74K ﹤0.01% 4799
2022
Q1 		$990K Sell
8,682
-47
-0.5% -$5.51K ﹤0.01% 4669
2021
Q4 		$1.26M Sell
8,729
-23
-0.3% -$4.17K ﹤0.01% 4591
2021
Q3 		$1.92M Sell
8,752
-109
-1% -$23.1K ﹤0.01% 4342
2021
Q2 		$2.06M Sell
8,861
-19,375
-69% -$4.93M ﹤0.01% 4258
2021
Q1 		$8.5M Buy
28,236
+2,071
+8% +$742K ﹤0.01% 3676
2020
Q4 		$9.84M Sell
26,165
-3,184
-11% -$1.12M ﹤0.01% 3369
2020
Q3 		$9.01M Sell
29,349
-384
-1% -$147K ﹤0.01% 3275
2020
Q2 		$11.2M Buy
29,733
+2,009
+7% +$569K ﹤0.01% 3119
2020
Q1 		$6.32M Sell
27,724
-561
-2% -$214K ﹤0.01% 3234
2019
Q4 		$15M Sell
28,285
-1,014
-3% -$549K ﹤0.01% 3042
2019
Q3 		$12.6M Buy
29,299
+652
+2% +$419K ﹤0.01% 3096
2019
Q2 		$34.1M Sell
28,647
-222
-0.8% -$265K ﹤0.01% 2548
2019
Q1 		$36M Buy
28,869
+420
+1% +$481K ﹤0.01% 2462
2018
Q4 		$26.9M Sell
28,449
-86
-0.3% -$103K ﹤0.01% 2567
2018
Q3 		$41.1M Buy
28,535
+503
+2% +$761K ﹤0.01% 2488
2018
Q2 		$45.2M Buy
28,032
+16,174
+136% +$27.8M ﹤0.01% 2415
2018
Q1 		$19.2M Buy
11,858
+1,939
+20% +$4.03M ﹤0.01% 2800
2017
Q4 		$16.7M Buy
9,919
+4,673
+89% +$6.18M ﹤0.01% 2874
2017
Q3 		$7.34M Buy
5,246
+398
+8% +$467K ﹤0.01% 3335
2017
Q2 		$5.41M Sell
4,848
-291
-6% -$240K ﹤0.01% 3453
2017
Q1 		$2.79M Buy
5,139
+5,134
+102,680% +$3.15M ﹤0.01% 3561
2016
Q4 		$3K Hold
5
– – ﹤0.01% 3582
2016
Q3 		$3K Hold
5
– – ﹤0.01% 3558
2016
Q2 		$3K Buy
+5
New +$3.44K ﹤0.01% 3580

Other funds holding CBIO

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock's CBIO Position: Q2 2026 in Review

BlackRock increased its Crescent Biopharma (CBIO) stake by 999% in Q2 2026, buying an estimated $22.6M and bringing the position to 1,271,762 shares worth $22.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

BlackRock first reported a position in CBIO in Q2 2016 and has held it in 41 quarters since. The position peaked at $45.2M in Q2 2018. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • BlackRock held 1,271,762 shares of Crescent Biopharma worth $22.9M as of Q2 2026.
  • BlackRock bought 1,156,037 Crescent Biopharma shares in Q2 2026, an estimated $22.6M.
  • Crescent Biopharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3165 holding.
  • BlackRock first reported a position in Crescent Biopharma in Q2 2016 and has held it in 41 quarters since.
  • BlackRock's Crescent Biopharma position peaked at $45.2M in Q2 2018.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.